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Colonisation of the colonic 
mucus gel layer with butyrogenic 
and hydrogenotropic bacteria 
in health and ulcerative colitis
Helen Earley1,2,4*, Grainne Lennon1,2,4, J. Calvin Coffey3,4, Desmond C. Winter2,4 & 
P. Ronan O’Connell1,2,4 
Butyrate is the primary energy source for colonocytes and is essential for mucosal integrity and 
repair. Butyrate deficiency as a result of colonic dysbiosis is a putative factor in ulcerative colitis (UC). 
Commensal microbes are butyrogenic, while others may inhibit butyrate, through hydrogenotropic 
activity. The aim of this study was to quantify butyrogenic and hydrogenotropic species and determine 
their relationship with inflammation within the colonic mucus gel layer (MGL). Mucosal brushings 
were obtained from 20 healthy controls (HC), 20 patients with active colitis (AC) and 14 with quiescent 
colitis (QUC). Abundance of each species was determined by RT-PCR. Inflammatory scores were 
available for each patient. Statistical analyses were performed using Mann–Whitney-U and Kruskall-
Wallis tests. Butyrogenic R. hominis was more abundant in health than UC (p < 0.005), prior to 
normalisation against total bacteria. Hydrogenotropic B. wadsworthia was reduced in AC compared 
to HC and QUC (p < 0.005). An inverse correlation existed between inflammation and R. hominis 
(ρ − 0.460, p < 0.005) and B. wadsworthia (ρ − 0.646, p < 0.005). Other hydrogenotropic species did not 
widely colonise the MGL. These data support a role for butyrogenic bacteria in UC. Butyrate deficiency 
in UC may be related to reduced microbial production, rather than inhibition by microbial by-products.
The colonic microbiota plays a crucial role in the maintenance of homeostasis in the  colon1. The short chain 
fatty acid (SCFA) butyrate is produced by microbial fermentation and is a key metabolite in the gastrointestinal 
 tract2,3. It is the primary energy source for colonocytes and also has anti-inflammatory actions, activates mucin 
release and protects the epithelial  barrier4–8.
Reduced colonic butyrate concentration has been reported in UC and has been proposed as a potential aetio-
logical factor in the pathogenesis of colonic  inflammation9. In UC, changes also occur in the composition of the 
 microbiota10,11, leading to the hypothesis that microbial factors may contribute to altered butyrate metabolism.
During mucin degradation, by-products are  released12,13, which may be utilised as substrates for other bacte-
rial species lacking mucolytic  properties13,14. One such group of hydrogenotropic bacteria utilise these substrates 
to produce the toxic metabolite hydrogen sulphide  (H2S)15–17, that may induce inflammation through direct 
toxicity to the epithelium or inhibition of butyrate  oxidation18–20. The most studied genus is  Desulfovibrio21–23. 
However, little information exists on the involvement of other, less abundant species with hydrogenotropic 
potential in UC (Desulfobacter, Desulfobulbus and Bilophila wadsworthia)24,25. Other commensal species, such 
as R. hominis, are involved in the production of  butyrate26. Butyrate levels in the colitic colon may be further 
reduced through reduced production by these  species27–37.
The outer layer of the MGL provides an energy source and a growth medium for mucus-associated 
 microbiota38,39, which represents a community distinct from luminal  bacteria40. This layer is therefore thought to 
represent the true host-microbial interface in the human  colon40,41 . The aims of this study were to determine the 
relative abundance of butyrogenic (R. hominis) and hydrogenotropic (Desulfobacter, Desulfobulbus and Bilophila 
wadsworthia) species and their relationship with inflammation within the mucus gel layer (MGL) of the colitic 
colon. This is the first study to quantitively analyse these species from brushings of the MGL.
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Materials and methods
Ethical approval, patient recruitment and sample collection. Ethical approval was obtained from 
the St. Vincent’s University Hospital Ethics and Medical Research Committee. All methods were carried out 
in accordance with the relevant guidelines and regulations. All volunteers were over 18 years old and written 
informed consent was obtained. Three patient cohorts were established; healthy controls (HC), patients with 
quiescent UC (QUC) and patients with active UC (AC). All patient data were anonymised and coded to ensure 
patient confidentiality.
Healthy controls were recruited when undergoing routine diagnostic day case colonoscopy. No macroscopic 
evidence of mucosal pathology was evident in these individuals. Patients were excluded from the study if they 
had a history of antibiotic usage or hospital admission in the six weeks prior to colonoscopy, history of irritable 
bowel syndrome (IBS), indeterminate colitis, gastrointestinal malignancy or previous colorectal surgery.
Patients with quiescent UC were identified as having previously diagnosed, histologically confirmed UC and 
were undergoing surveillance colonoscopy. Exclusion criteria were as outlined above or evidence of UC associ-
ated dysplasia. Bowel preparations received by all patients undergoing colonoscopy were polyethylene glycol 
and sodium picosulphate based.
Patients in the AC cohort were recruited prior to undergoing surgical resection for disease refractory to 
medical management or those with acutely active UC failing to respond to rescue therapy (intravenous steroids, 
biologics or cyclosporine). Patients had not received bowel preparation prior to undergoing surgery, but had 
received a single dose of intravenous antibiotics prior to induction of anaesthesia, as per hospital protocol.
A biobank of clinical specimens was present in the form of extracted DNA in the School of Medicine and 
Medical Sciences in UCD. These DNA extracts were isolated from colonic mucus brushings and stored in sterile 
micro-centrifuge tubes at − 20 °C. Mucus brush samples were obtained using a Microbiological Protected Speci-
men Brush (Hobbs Medical Inc., Stafford Springs, Connecticut, USA). Samples were taken from the superficial 
layer of colonic mucus as previously  described40. DNA was extracted using a Qiagen DNA Mini Kit (Qiagen, 
Hilden, Germany). The biobank of samples consisted of DNA from 20 HCs, 14 patients with QUC and 20 patients 
with AC. For each patient, samples were collected from four areas of the colon; caecum, transverse colon, left 
colon and rectum.
For each clinical sample the total copy number of bacteria per mg of mucus had previously been determined 
by quantitative RT-PCR42. Inflammatory scores had also been determined as previously  described41. These data 
were available in a database for use as part of this study.
Construction of plasmid DNA standards. A series of plasmid DNA standards was generated to enable 
calculation of each bacterial copy number in each sample. In brief, freeze dried cultures of reference strains 
of Desulfobacter curvatus (ATCC 43,919)43, Desulfobulbus propionicus (ATCC 33,891)43, Bilophila wadsworthia 
(ATCC49260)44 (ATCC, Manassas, V.A., U.S.A.) and a clinical sample of R. Hominis were cultured in their 
respective culture media as previously  outlined42,45,46. Cultures were placed in a shaking incubator at 200 rpm 
at 37 °C for 72 h under anaerobic conditions achieved by the use of AnaeroGen anaerobic gas packs (Oxoid, 
Basingstoke, UK). DNA was extracted using a series of four heat freeze cycles at − 80 °C and 100 °C. Extracted 
DNA as outlined was used to generate positive controls for each bacterial target. Conventional PCR targeting the 
16S rRNA gene of bacterial targets was performed using previously published oligonucleotide primers sourced 
from Eurofins MWG GmbH (Eurofins MWG GmbH, Ebersberg, Germany) as outlined in Table 1. Assays for 
D. propionicus and D. curvatus were carried containing 1.25U GoTaqDNA polymerase (Promega Madison, WI, 
U.S.A.), 5 × GoTaq Reaction Buffer (Promega), dNTPs at a final concentration of 0.2 mM, forward and reverse 
primers at final concentrations as outlined in Table 1 and 5 µl of DNA template. Assays for B. wadsworthia, and 
R. hominis contained 2X My TaqRed Mix (Bioline, London, UK), primers at concentrations outlined in Table 1. 
The amplicons generated were cloned into a TOPO vector using the TOPO TA cloning system. DNA from the 
recombinant plasmid mini-preps were purified using the QIAprep Spin MiniPrep kit (Qiagen). The total weight 
per recombinant plasmid was calculated and this was used to generate a series of DNA standards of known copy 
number of the target sequence.
Detection and quantification of microbes in mucus brushings. For each clinical sample the total 
copy number of bacteria per mg of mucus had previously been determined by quantitative RT-PCR45.
Table 1.  16S rRNA targeted PCR primer sequences used in this study and their expected amplicon sizes. 
*Denotes the use of a degenerate base pair. Y = C/T, R = A/G, S = C/G, W = A/T, K = G/T.
Bacterial target Forward Primer (5′–3′) Reverse Primer (5′–3′) Product Size (bp) Concentration (nM) References
D. propionicus CGC GTA GAT AAC CTG TCY TCA TG*
GTA GKA CGT GTG TAG 
CCC TGG TC 1120 250
63
D. curvatus GAT AAT CTG CCT TCA AGC CTG G
CYY YYY GCR RAG TCG 
STG CCC T* 1150 250
63
B. wadsworthia CGT GTG AAT AAT GCG AGG G
TCT CCG GTA CTC AAG 
CGT G 207 200
64
R. hominis TAC TGC ATT GGA AAC TGT CG
CGG CAC CGA AGA 
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RT PCR using an assay specific for the 16S rRNA gene of each bacterial target was performed using primers 
outlined above. All PCR reactions for the targets D. propionicus, D. curvatus and B. wadsworthia were carried 
out on an Applied Biosystems7900HT Fast Real-Time PCR machine (Applied Biosystems Foster City, CA, USA.) 
using the primers outlined in Table 1. Each reaction was performed in duplicate and carried out in an optical 
grade 384-well plate at a final volume of 20 µl. Each reaction consisted of 1X SyberGreen PCR Master Mix 
(Applied Biosystems), forward and reverse primers at concentrations outlined in Table 1 and 4 µl of template 
DNA. For all bacterial targets standard cycling conditions and melt curve analysis were employed, plus addi-
tional annealing stages. For D. propionicus and D. curvatus incubations of 72 °C for 30 s and 79 °C for 10 s were 
included. For B. wadsworthia an additional annealing stage at 79 °C for 10 s was added. Reactions for R. hominis 
were carried out on an Illumina Eco Real Time PCR system machine (Illumina, San Diego, CA, USA) using 
standard annealing and melt curve analysis. Thermocycling conditions for R. hominis were; 40 cycles at 95 °C 
for 30 s, elongation at 55ºC for 60 s and annealing at 72ºC for 10 s. Each reaction was carried out in an optical 
grade 48-well plate at a final reaction volume of 10 µl, containing 1X SensiFAST SYBR No-ROX Mix (Bioline) 
appropriate forward and reverse primers at final concentrations outlined in Table 1 and 4 µl of DNA template. 
All assays included water as a negative control and positive controls.
RT-PCR data analysis. Data analysis for all PCR assays performed on the Applied Biosystems platform 
was performed using SDS 2.4 software (Applied Biosystems). For assays performed on the Illumina platform 
(Illumina) EcoStudy software v 5.0 (Illumina) was used. Target copy number in each sample was determined 
based on the fold change  (2-∆Ct) relative to the  107 copies/µl standard. Copy numbers were normalised for dilu-
tion volume, elution volume, DNA concentration and sample weight and for total bacterial copy numbers in 
each sample.
Statistical analysis. Normalised data were exported to SPSS statistics, version 20.0 (SPSS statistics, IBM, 
London, U.K.) for statistical analysis. Data were tested for normality of distribution, and statistical comparisons 
were performed based on Mann–Whitney U test and Kruskal–Wallis comparisons. Methods are summarised 
in Fig. 1.
Figure 1.  Schematic representing work flow through sample collection to data analysis.
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Results
Patient demographics. Fifty-four individuals were included in the study, comprising 20 patients with AC, 
14 with QUC and 20 HC. Patients in the AC group were undergoing colectomy for disease refractory to medical 
management. No patients in this group had presented with an acute surgical emergency. Of the patients in the 
quiescent group, 5 underwent colonoscopy to monitor disease activity, the remaining 9 patients were undergo-
ing screening colonoscopy procedures, eight of whom had disease duration of greater than ten years. As a result, 
the mean time since diagnosis was longer in the quiescent group than in the acute colitis group. In addition, the 
mean age in the QUC cohort (49 yrs) was also older than in the AC cohort (36 yrs). The mean age in the HC 
cohort was 48.2 yrs which closely resembled that of the quiescent cohort. The mean Mayo score of AC patients 
was 10.3, whereas the QUC cohort had a mean of 0.25. Information with regard to smoking status, medication 
and previous appendectomy was available. A summary of patient demographics is outlined in Table 2.
Colonisation of the colon with butyrogenic species R. hominis. R. hominis was detected in all indi-
viduals in the three cohorts. The abundance of R. hominis was significantly reduced in AC compared to HC and 
patients with QUC (Table 3, Fig. 2(i)). No significant difference was detected between the HC and those with 
QUC (Table 3). After normalisation for total bacterial copy number, no significant difference in relative abun-
dance between any patient cohort was noted (Table 3). The reduction in abundance of R. hominis in the acute 
UC cohort compared to HC and QUC was observed in all four areas of the colon, caecum, transverse colon, left 
colon and rectum (Table 4). No significant difference in R. hominis abundance was detected between health and 
QUC across all four colonic regions. 
Colonisation of the MGL with hydrogenotropic bacteria. Low rates of colonisation with the sulphate 
reducing D. curvatus and D. propionicus species were detected in all patient cohorts (Fig. 3). 40% of patients were 
positive for D. propionicus in the HC and AC cohorts, and 10% of patients in the QUC cohort. D curvatus was 
detected in 10% of patients with QUC. This species was not detected in healthy individuals or the AC cohort 
(Fig. 3). Given these findings, these microbes were eliminated from further study.
B. wadsworthia demonstrated a high colonisation rate in all three cohorts (HC 100%, QUC 90%, AC 95%) 
(Fig. 3). Subsequent quantitative analysis was performed on this species. The abundance of B. wadsworthia was 
significantly reduced in patients with acute UC compared to health and patients with quiescent UC (Table 5, 
Fig. 4). No significant difference was detected between the healthy controls and those with quiescent UC (Table 5). 
Table 2.  Summary of characteristics of individuals in each cohort.
HC QUC AC
n 20 14 20
Age (years) 48.2 (21–77) 50.07 (29–72) 37.4 (23–66)
Gender (M/F) 16/4 10/4 12/8
Time since diagnosis (years) n/a 18 (10–33) 5 (2–14)















Steroid n/a 1 12
5-ASA n/a 7 8
Azathioprine n/a 4 0
Infliximab n/a 0 12
Mean Mayo Score 0 0.25 10.3
Table 3.  Median copy number/mg and median relative abundance of R. hominis after normalisation for total 
bacterial copy number in each patient cohort. p values for inter-cohort comparisons.
Cohort n Median Copy No IQR Cohort Comparison p value
HC 20 1.13E + 5 3.37E + 5 HC-QUC 0.072
QUC 14 1.87E + 5 1.03E + 6 HC-AC 0.000
AC 20 8.06E + 2 5.30E + 3 QUC – AC 0.000
Cohort n Median Normalised Copy No IQR Cohort Comparison p value
HC 20 3.41E−3 1.72E−2 HC-QUC 0.388
QUC 14 6.89E−3 4.40E−2 HC-AC 0.631
AC 20 5.17E−3 3.31E−2 QUC – AC 0.627
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Figure 2.  Boxplots representing inter-cohort comparisons of R. hominis. Healthy controls are represented in 
green, patents with quiescent UC in orange and patients with acute UC in red. * denotes p < 0.05. Loco regional 
comparison along the longitudinal axis of the colon in the three patient cohorts.
Table 4.  Comparison of R. hominis copy number and relative abundance on a loco-regional basis.







HC-QUC HC-ACact QUC-ACMedian IQR Median IQR Median IQR
Caecum 16 1.00E+5 3.75E+5 11 8.93E+4 1.27E+6 17 1.61E+3 4.56E+4 0.716 0.000 0.001
Transverse 17 2.20E+5 3.51E+5 13 8.56E+4 2.47E+6 16 7.62E+2 4.85E+3 0.869 0.000 0.000
Left 15 6.57E+4 1.85E+5 11 2.62E+5 2.19E+6 16 8.87E+2 2.29E+3 0.039 0.000 0.000
Rectum 15 5.93E+4 5.08E+5 11 2.25E+5 9.55E+5 16 4.64E+2 1.46E+3 0.305 0.000 0.000







HC-QUC HC-AC QUC-ACMedian IQR Median IQR Median IQR
Caecum 15 1.99E−3 1.33E−2 9 1.04E−2 8.62E−2 13 4.79E−3 1.37E−2 0.387 0.982 0.301
Transverse 16 2.93E−3 2.38E−2 10 8.62E−3 1.27E−2 14 3.37E−3 2.10E−2 0.916 0.934 0.815
Left 15 2.76E−3 2.76E−2 9 1.70E−3 6.84E−2 15 3.70E−3 5.32E−2 0.698 .0.395 0.929
Rectum 15 9.95E−3 1.70E−2 10 7.40E−3 4.45E−2 14 1.02E−2 3.52E−2 1.000 0.727 0.953
Figure 3.  Colonisation rates of each bacterial target in each patient cohort. Healthy controls are represented in 
green, patients with quiescent UC in orange and patients with acute UC in red.
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After normalisation for total bacterial copy number, a persistent significant reduction in the relative abundance 
of B. wadsworthia was noted in the acute UC cohort compared to the healthy cohort (Table 5). No significant 
difference in normalised B. wadsworthia copy number was noted between healthy patients and patients with 
quiescent UC, or between the quiescent UC group and those with acute colitis (Table 5). The reduction in abun-
dance of B. wadsworthia in the acute UC cohort compared to health and quiescent UC was observed in all four 
areas of the colon, caecum, transverse colon, left colon and rectum. No significant difference in B. wadsworthia 
Table 5.  Median copy number/mg and median relative abundance of B. wadsworthia after normalisation for 
total bacterial copy number in each patient cohort.
Cohort n Median copy No. IQR Cohort comparison p value
HC 20 1.18E + 04 2.60E + 04 HC−QUC 0.546
QUC 14 1.35E + 04 3.00E + 04 HC-AC 0.000
AC 20 5.05E + 00 2.32E + 02 QUC–AC 0.000
Cohort n Median normalised copy No. IQR Cohort comparison p value
HC 20 3.64E–04 1.94E–02 HC-QUC 0.467
QUC 14 7.75E–04 3.27E–03 HC-AC 0.030
AC 20 1.92E–04 1.85E–03 QUC–AC 0.150
Figure 4.  Boxplots representing inter-cohort comparisons of B. wadsworthia copy number Healthy controls are 
represented in green, patients with quiescent UC in orange and patients with acute UC in red. * denotes p < 0.05. 
Comparison between areas of the colon.
Table 6.  Comparison of B. wadsworthia copy number and relative abundance on a loco-regional basis.







HC-QUC HC-AC QUC-ACMedian IQR Median IQR Median IQR
Caecum 18 8.39E + 03 1.34E + 04 13 1.40E + 04 2.92E + 04 16 1.02E + 01 1.68E + 02 0.590 0.000 0.000
Transverse 18 1.49E + 04 3.20E + 04 12 9.97E + 03 4.92E + 04 15 5.05E + 00 3.27E + 02 0.611 0.000 0.000
Left 17 1.17E + 04 3.14E + 04 11 1.46E + 04 3.48E + 04 14 7.10E + 00 1.50E + 03 0.869 0.000 0.001
Rectum 19 1.74E + 04 2.86E + 04 13 7.43E + 03 4.14E + 04 13 1.89E + 00 2.02E + 02 0.219 0.000 0.002







HC-QUC HC-AC QUC-ACMedian IQR Median IQR Median IQR
Caecum 18 2.32E–04 8.63E–03 13 4.44E–04 2.01E–02 16 5.36E–05 1.39E–03 0.701 0.241 0.635
Transverse 18 4.38E–04 1.66E–02 12 9.46E–04 3.02E–03 15 6.47E0–6 2.51E–03 0.421 0.072 0.157
Left 17 2.65E–04 9.10E–03 11 1.34E–03 3.44E–03 14 8.39E–04 1.14E–02 0.729 0.771 0.953
Rectum 19 5.81E–04 6.13E–02 13 4.29E–04 3.88E–03 13 2.55E–04 7.87E–04 0.388 0.189 0.369
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abundance was detected between health and quiescent UC across all four colonic regions (Table 6, Fig. 4.). After 
normalisation against total-bacterial copy number, no significant difference was noted between patients with 
acute UC or quiescent UC compared to health in any of the four colonic regions examined (Table 6).
Correlation of butyrogenic and hydrogenotropic bacteria with inflammatory cell infil-
trates. To determine whether the abundance of R. hominis or B. wadsworthia in the colon was associated 
with markers of inflammation, correlations with inflammatory cell infiltrates were performed. A negative cor-
relation existed between inflammatory cell infiltrate and abundance of B. wadsworthia, (ρ − 0.646, p = 0.000). A 
negative association was also found between inflammatory cell infiltrate and abundance of R. hominis, (ρ − 0.460, 
p = 0.000).
Discussion
The present study uses protected specimen brushings of the colonic mucosa as the sampling  method40. This 
unique approach to studying the innate microbiota has several advantages. It minimises contamination with 
luminal contents compared to faecal sampling and obtains a higher proportion of bacterial DNA than host DNA 
when compared to mucosal  biopsies40,47. Faecal samples, the MGL and mucosa have each been shown to harbour 
distinct microbial  communities48. Mucus brushings are believed to yield findings that are more representative 
of the true burden of these species within the outer layer of the MGL, which represents the true host-microbial 
interface in the human  colon39,40,47.
The primary aim of this study was to perform quantitative analysis of R. hominis, a species known to produce 
substantial amounts of butyrate in vitro49. This species widely colonised the MGL in health and UC, indicating 
that this is an ubiquitous member of the innate microflora. Its’ abundance was reduced in patients with AC 
compared to health and QUC. This reduction was observed in all four colonic regions, supporting the hypothesis 
that UC is associated with a global dysbiosis and the concept of spatial homogeneity along the longitudinal axis 
of the  colon42,48. An inverse correlation between R. hominis abundance and inflammatory cell infiltrates was 
demonstrated, indicating that depletion of this species is a feature of inflammation in the colitic colon.
In keeping with these data, reductions in the abundance of this species, as well as an inverse correlation with 
disease severity, have been reported in UC in previous studies based on faecal  sampling28,32. However, studies of 
mucosal biopsies yielded conflicting  results50,51. Willing et al.reported a reduction in R. hominis in patients with 
ileal CD, but not  UC50, while Lepage et al.reported no reduction in the species in mucosal biopsies of twins with 
 UC51. These findings, combined with the observation by Machiels et al.that a stable reduction occurred in the 
faeces of patients with quiescent disease, led to the hypothesis that alterations in Roseburia abundance may play 
a role in the study of the transient microbiota, rather than the adherent  microbiota28. The current study chal-
lenges this theory, suggesting that the reduction in R. hominis contributes to the dysbiosis of the MGL adherent 
microbiota in the inflamed colon, with abundances returning towards healthy levels when disease is in remission. 
R. hominis has been shown to have anti-inflammatory mechanisms in vitro52. It is tempting to hypothesise that 
this is related to the production of butyrate however, the authors acknowledge that this cannot be inferred from 
compositional data alone.
This study also aimed to determine colonisation patterns of  H2S producing species. Desulfovibrio remains the 
most studied of these bacteria and to date a consensus has not been reached as to their precise role in  UC25,45,53,54. 
Few studies analysed other low-abundance microbes such as D. desulfuricans and D. propionicus, both of which 
are capable of foraging sulfate and producing  H2S24. No data currently exist pertaining to the involvement of 
these species in UC. This study demonstrated low colonisation rates of D. desulfuricans and D. propionicus in 
both health and UC. 40% of healthy subjects were positive for D. curvatus in the current study, in keeping with 
data from Gibson et al., who reported hydrogenotropic species in 50% of faecal  samples55. On the other hand, 
it is at odds Nava et al.who detected both species in mucosal biopsies of 25 healthy  subjects56. It should also be 
noted that in the aforementioned study, the species Desulfovibrio accounted for the majority of hydrogenotropic 
present. Previous work from our laboratory demonstrated a high rate of colonisation with Desulfovibrio45 in 
these patient samples. Desulfovibrio may be the dominant species of sulphate reducing bacteria colonising this 
patient cohort also. Given the low colonisation rates of D. desulfuricans and D. proprionicus in UC, there is no 
compelling evidence of an association between these species and UC in the present study.
B. wadsworthia was present at detectable levels in the majority of individuals in this study. These data demon-
strate a significant reduction in B. wadsworthia in patients with AC compared to healthy individuals and those 
with QUC. The reduced abundance in patients with AC compared to healthy individuals remained significant 
after normalisation against total bacterial counts. The inverse correlation between B. wadsworthia abundance 
and inflammatory score confirm that a reduction in abundance of this species is a feature of the inflamed colon. 
Although these findings are not in keeping with the hypothesis of increased activity of hydrogenotropic bac-
teria in UC, the finding is nonetheless significant. These data suggest a tentative link between this species and 
dysbiosis in AC.
These results are consistent with previously published findings using faecal samples, reporting a reduction 
in B.wadsworthia in patients with Crohn’s disease before treatment compared to  health25. However it should be 
noted that these findings differ from those in murine models, where B. wadsworthia has been reported to act as 
a pathobiont, promoting the development of  inflammation57,58. Evidence suggests that In vivo results of murine 
models cannot always be extrapolated easily to  humans59,60, which should be considered when interpreting the 
contrasting results pertaining to this species reported in human and murine models.
In this study, normalisation of data against total bacterial copy number was performed to reduce potential 
reporting errors by minimising the effect of between-sample variation and taking the efficiency of the quantifica-
tion procedure into account for both species investigated. These data are more representative of the actual burden 
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of the target in the MGL. However, normalisation negated the significant difference in abundance observed 
between health and acute UC when analysis was based on raw copy numbers at each of the four colonic regions 
examined. This may be due to the fact that individually, these species account for a small proportion of the overall 
bacterial load at any given site in the colon.
It is likely that several factors contribute to the observed reduction in abundance in these species in UC. 
Changes in the ecosystem of the MGL as a result of the inflammatory process may result in suboptimal con-
ditions for bacterial survival. To date, no study has specifically addressed the potential interactions between 
hydrogenotropic, butyrogenic and other species within the MGL in the colitic colon. The authors have previously 
demonstrated a reduction in mucolytic bacteria in  UC41, which due to reduced mucin degradation, may lead to a 
lack of substrate for these bacteria. Hydrogenotropic bacteria have also been shown to impact host  physiology61. 
It is possible that B. wadsworthia has properties that enable SCFA production. A recently published study dem-
onstrated an association between B. wadsworthia and higher butyric acid concentrations in faecal samples of 
healthy  infants62, suggesting a potential link between the species and SCFA production in the human colon.
This study investigated the microbiological basis of UC as an energy deficiency disease, with specific focus 
on butyrogenic and hydrogenotropic bacteria at the level of the MGL. In keeping with the hypothesis that UC is 
associated with reduced butyrate concentrations, reductions in the abundance of R. hominis were noted. However 
reduced abundance of the hydrogenotropic B. wadsworthia was also observed in the colitic colon in this study. 
These data suggest that the reported lack of butyrate in the colitic colon may be a result of a lack of butyrogenic 
bacteria, rather than bacterial inhibition by microbial by-products such as  H2S. Furthermore, altered abundances 
of these species are associated with active inflammation in UC. Overall, these data suggest that reductions in 
these species are a feature of the altered microbial signature of the MGL in UC.
Limitations
The authors acknowledge that the current study has some limitations. It is possible that the use of bowel prepara-
tion may have resulted in a loss of some loosely adherent microbes in the patients undergoing colonoscopy (HC 
ad), however, this would not account for the low colonisation rates in patients with acute UC, as this cohort did 
not receive bowel preparation prior to surgery. This would be difficult to control for, as adequate bowel prepara-
tion is a prerequisite for successful colonoscopy. This study did not determine whether the observed alterations in 
microbes equated to alterations in butyrate levels in the colon. Further functional studies are warranted to validate 
these findings. Finally, as with many studies of the microbiota, the authors acknowledge that it is not possible to 
determine from these data whether the observed changes are a potential driving force behind the pathogenesis 
of inflammation, or arising as a result of the inflammatory process. The association between these microbial 
changes and UC warrants further investigation, with a view to establishing whether a cause-effect relationship 
indeed exists, and whether manipulation of the dysbiosis in UC will have clinical applications in the future.
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